HPPI to transfer SUBA-Itraconazole BCCNS clinical program to Mayne Pharma in consideration of up to $5 million in new funding from Mayne Pharma and a 9% royalty on future SUBA-Itraconazole BCCNS sales in the U.S.
With new funding, HPPI to move towards IND filing during 2019 and recruitment to initiate human trials for SUBA-Itraconazole Prostate
HPPI also to pursue expansion of product candidate pipeline with non-SUBA itraconazole analogue technology with University of Connecticut
PR Newswire
TAMPA, Fla., Dec. 17, 2018
